drugset / Trial / NCT00472368

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

NCT00472368

Phase 1 Completed 4 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This single center study will help determine the absorption, metabolism, and excretion of LBH589 and to assess the safety and efficacy of LBH589 in advanced cancer patients for whom no standard therapy exists.

Timeline

Start
2007-05
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 20 mg Oral

Indications

No indication recorded.